Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Nicole Verdun has exited the FDA as CBER director, allowing Vinay Prasad to consolidate power within the agency. Prasad is seen as a stabilizing and trustworthy figure within the rapidly changing FDA, especially since the departure of Peter Marks in late March. Novavax is adapting to regulatory uncertainty following the delayed approval of its next-generation COVID-19 vaccine. The company is relying on agility and a diverse pipeline to navigate changing regulations. Additionally, the FDA has frozen trials shipping cells to countries like China due to new export control policies. Exemptions have allowed companies to ship biological materials overseas, but this practice is now being restricted. Zealand's GLP-1/GLP-2 drug has shown promising results in weight loss trials, with analysts believing there is potential for further improvement. Intellia Therapeutics aims to transform the lives of people with severe diseases through genome editing treatments. Overall, the biotech industry is facing various challenges and changes, requiring companies to stay adaptable and innovative.

Support the show